FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

78 letters match. Newest first.

  1. Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

    FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

    High risk
  2. Guangzhou Jiugong Research And Development Biotechnology Co., Ltd.

    Guangzhou Jiugong, an OTC drug maker, used a color additive FDA cancelled in 1976 and fell short of CGMP.

    High risk
  3. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium
  4. FairyGene, Inc.

    FDA cites FairyGene, a Bristol, PA contract manufacturer, for unsanitary facility and cleaning practices and for selling five unapproved drug balms.

    High risk
  5. ABS Corporation

    ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.

    High risk
  6. Almon Healthcare Private Limited

    Almon Healthcare, an Indian active pharmaceutical ingredient (API) maker, knowingly used mislabeled, untested raw material and shipped affected drugs to the U.S.

    High risk
  7. Flowchem Pharma Private Limited

    FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.

    High risk
  8. Diasol, Inc.

    Diasol sold unapproved citric acid hemodialysis disinfectants and had quality system violations, FDA says.

    High risk
  9. AQ USA Inc., d.b.a Ross Healthcare Inc.

    FDA warns AQ USA/Ross Healthcare over current good manufacturing practice violations in drugs, including missing microbial testing and inadequate component and stability controls.

    High risk
  10. Sklar Personal Care Inc.

    Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.

    High risk
  11. Cdymax India Pharma Private Limited

    FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.

    High risk
  12. Scientific Protein Laboratories, LLC

    FDA warns Scientific Protein Laboratories over manufacturing failures in animal-derived APIs, including equipment particles and inadequate investigations.

    High risk
  13. Gracie's Kitchens, Inc.

    FDA warns Gracie's Kitchens over Listeria on RTE produce food-contact surfaces and sanitation failures.

    High risk
  14. Chengdu Brilliant Biopharmaceutical Co., Ltd.

    FDA warns Chengdu Brilliant over CGMP failures in semaglutide API, including no process validation and missing raw-material identity tests.

    High risk
  15. LeMaitre Vascular, Inc.

    LeMaitre Vascular's Artegraft graft plant in New Jersey drew an FDA warning letter for water, sterilization and recall-reporting failures.

    High risk
  16. Shiva Analyticals Private Limited

    FDA warned Shiva Analyticals, an Indian contract drug testing lab, that inadequate OOS investigations and data integrity failures adulterated tested drugs.

    High risk
  17. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  18. Dyno Manufacturing, Inc.

    Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.

    High risk
  19. BEO Pharma Inc. dba BEO Pharmaceuticals Inc.

    FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.

    High risk
  20. Yangzhou Sion Commodity Co., Ltd.

    FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.

    High risk
  21. Tyche Industries Ltd

    FDA warned Tyche Industries over falsified records, dirty equipment, and untested raw materials at its API plant.

    High risk
  22. Chengdu Innovation Pharmaceutical Co., Ltd.

    FDA warned Chengdu Innovation Pharmaceutical over CGMP (manufacturing quality rules) failures in API (drug ingredient) manufacturing, including no identity testing of incoming materials.

    High risk
  23. Colgate-Palmolive/Tom's of Maine, Inc.

    FDA cited Tom's of Maine for CGMP failures after finding objectionable microbes in water and toothpaste and inadequate complaint handling.

    High risk
  24. Choice All Natural, Inc. dba Om Botanical

    FDA warns Om Botanical of Apex, NC over filthy manufacturing, an unapproved rash cream, and lapsed FDA registration.

    High risk
  25. Kaylaan LLC

    FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.

    High risk
  26. Donggang Wanrui Food Co., Ltd.

    Donggang Wanrui Food Co., Ltd. lacked required seafood safety plan monitoring and records for raw frozen octopus and crab.

    High risk
  27. Sakhon Wattana Thang Chue Hah

    FDA warns Thai fish sauce maker Sakhon Wattana Thang Chue Hah over missing safety controls for pathogens and histamine.

    High risk
  28. Aruba Aloe Balm N.V.

    Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.

    High risk
  29. Natuzen Co., Ltd.

    Natuzen Co., Ltd. failed drug manufacturing rules for OTC products including Atoren Hand Sanitizer, with no methanol testing, cleaning validation, or quality unit.

    High risk
  30. Vintage Chemical Inc.

    FDA warned Vintage Chemical after an inspection found over-the-counter hand soap and sanitizer made on equipment shared with industrial cleaners.

    High risk
  31. Master Paints & Chemicals Corp.

    FDA warned Master Paints & Chemicals Corp. over inadequate testing and quality oversight for OTC drugs including hand sanitizer.

    High risk
  32. FirstCham Co., Ltd.

    FDA warns FirstCham over current good manufacturing practice violations and misbranding of Soo'Ae hand sanitizing wipes.

    High risk
  33. Colgin, Inc.

    FDA warned Colgin that its OTC drug ChigaRid External Analgesic violated manufacturing quality rules, including expired ingredients and missing tests.

    High risk
  34. Nantong Furuida Packaging Products Co., Ltd.

    Nantong Furuida, an over-the-counter drug manufacturer, failed required manufacturing controls and methanol checks, leading to an FDA import alert.

    High risk
  35. Xiamen Wally Bath Manufacture Co., Ltd.

    FDA warns Xiamen Wally Bath over current good manufacturing practice failures for over-the-counter hand sanitizer, including raw material and release testing gaps.

    High risk
  36. Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi

    FDA found manufacturing violations at Turkish OTC drug maker, including missing identity, release, and stability testing for hand sanitizers.

    High risk
  37. Green Pharmaceutical Co. Ltd.

    FDA warns South Korea's Green Pharmaceutical over OTC drug CGMP failures, including missing identity testing and weak quality unit.

    High risk
  38. Laavo Clean, S.A. de C.V.

    Laavo Clean's alcohol-free hand sanitizers had wrong benzalkonium chloride strength and were refused at US border.

    High risk
  39. Fancystage Unipessoal, LDA

    Portugal OTC drug maker Fancystage Unipessoal skipped identity testing of high-risk ingredients and lacked quality-unit control, FDA says.

    High risk
  40. Manzanola Feeds, LLC

    Manzanola Feeds' alfalfa horse cubes contained Clostridium botulinum toxin type C and animal hair, causing an outbreak and recall.

    High risk
  41. Skyless, LLC

    FDA cited Skyless, LLC for CGMP failures and for selling three X-PASMO topical analgesic ointments as unapproved and misbranded drugs.

    High risk
  42. Getsch+Hiller Medizintechnik GmbH

    FDA warned Getsch+Hiller about unapproved reusable laparoscopic tips and missing quality records at its German plant.

    High risk
  43. Salon Technologies International, Inc.

    FDA warns Salon Technologies International that its hand sanitizers contained unacceptable acetaldehyde, acetal and benzene impurities and were adulterated.

    High risk
  44. McConnell Labs Inc.

    McConnell Labs Inc. released hand sanitizers without raw material identity, finished product, or stability testing, FDA says.

    High risk
  45. DDI Multinacional S.A. de C.V.

    DDI Multinacional hand sanitizers labeled 70% ethanol contained up to 60% methanol, leading to adulteration and import alert.

    High risk
  46. Industrias Cklass S. de R.L. de C.V.

    FDA found Industrias Cklass hand sanitizer labeled 70% ethanol contained 19% ethanol and 48% methanol and was refused U.S. admission.

    High risk
  47. David Cosmetic Co., Ltd.

    FDA lab testing found benzene, a cancer-causing impurity, at about 6 ppm in David Cosmetic's CALA hand sanitizer, making it adulterated.

    High risk
  48. Maquiladora Miniara SA de CV

    Maquiladora Miniara's Shine and clean Hand Sanitizer Gel was found to contain methanol instead of labeled ethanol.

    High risk
  49. Bionateo Sp. z.o.o.

    Bionateo, a Polish drugmaker, shipped hand sanitizer contaminated with methanol and isopropanol that FDA refused at the U.S. border.

    High risk
  50. AriBio H&B Co., Ltd.

    FDA warns AriBio H&B over subpotent Hand Sanitizer Original labeled 70% ethanol but tested at 58%, plus misbranding.

    High risk